SLV 339

Drug Profile

SLV 339

Alternative Names: SLV339

Latest Information Update: 13 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novozymes A/S; Solvay
  • Class Pancreatic enzymes
  • Mechanism of Action Lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders

Highest Development Phases

  • Discontinued Pancreatic disorders

Most Recent Events

  • 07 Mar 2009 Discontinued - Phase-II for Pancreatic disorders in European Union (PO)
  • 03 Oct 2006 Phase-I clinical trials in Pancreatic disorders in European Union (unspecified route)
  • 03 Oct 2006 SLV 339 received Orphan Drug status for Pancreatic disorders in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top